Skip to main content
. 2020 Apr 20;103(2):176–182. doi: 10.1093/biolre/ioaa052

Figure 3.

Figure 3

The iterative cycle for designing, synthesizing, and evaluating sAC inhibitors. Starting from LRE1, the workflow used to identify a preclinical development candidate includes activities performed in the Levin/Buck laboratory (light blue), the Steegborn laboratory (orange), or at TDI or TDI-managed CROs (green). In vitro efficacy models include both cell-based cyclase assay and in vitro efficacy mouse sperm. Structural biology information is used to model and design new compounds.